TRIM37控制了癌症特异性对PLK4抑制的脆弱性
Franz Meitinger1, Midori Ohta2, Kian-Yong Lee2
1Ludwig Institute for Cancer Research, La Jolla, CA, USA. fmeitinger@ucsd.edu.
通过向TRIM37水平,PLK4抑制剂可以治疗癌症. 低TRIM37有助于PLK4抑制后的癌细胞增殖,而高TRIM37则导致线粒衰竭,从而提供了新的癌症治疗策略.
科学领域:
- 细胞生物学
- 癌症生物学
- 分子瘤学
背景情况:
- 中心体对于微管组织和线粒组装至关重要.
- 中心细胞复制是由PLK4激酶调节的.
- 抑制PLK4导致细胞缺少细胞中心体,影响细胞分裂.
研究的目的:
- 在PLK4抑制后,研究TRIM37在中心组合中的作用.
- 根据TRIM37水平来确定PLK4抑制剂是否可以作为癌症治疗药物.
- 阐明TRIM37影响线粒细胞进展和癌细胞活力的机制.
主要方法:
- 化学抑制PLK4.
- 对TRIM37水平及其对细胞分裂的影响的分析.
- 研究TRIM37在中心体独立微管组织中的作用.
- 对TRIM37对CEP192降解的影响的评估
- 与癌症类型和PLK4抑制剂敏感性的TRIM37基因拷贝数变化的相关性.
主要成果:
- 在PLK4抑制后的中枢组合严重依赖TRIM37水平.
- 低TRIM37加速组装并改善增殖;高TRIM37导致线粒衰竭.
- TRIM37防止PLK4自组装到子宫外微管组织中心.
- 提升的TRIM37导致CEP192降解,抑制了螺旋组装.
- 具有Chr17q增强的癌症 (例如神经母细胞瘤,乳腺癌) 对PLK4抑制敏感.
结论:
- TRIM37是癌细胞对PLK4抑制的关键决定因素.
- 将TRIM37与PLK4抑制剂结合为特定癌症提供潜在的治疗策略.
- 在TRIM37位点的基因组变化为预测对基于PLK4的治疗反应提供了一个生物标志物.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
Abnormal Proliferation
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Negative Regulator Molecules
